Liquid Learn for healthcare & pharma

Govern AI across care delivery and the medicines lifecycle.

Connect clinical, scientific and quality oversight.

Bring AI service information, accountable owners, controls, training and evidence into one shared governance environment. Give healthcare and pharmaceutical teams a clear record of how AI is used, who oversees it and what supports the next decision.

For health systems, care providers, pharmaceutical and biotech companies, and their research, manufacturing and implementation partners.

A clinician, clinical safety colleague and technology lead discussing a service workflow together.
Clinical judgment. Shared responsibility. A record that continues.AI-generated editorial illustration.
The work behind responsible adoption

A promising tool still needs a governed service.

AI can arrive through a pilot, a purchased platform or a new feature in an existing system. The governance work crosses clinical practice, research, quality, procurement and operations. It needs to stay connected as the service changes.

01 / Suitability

Evidence for your setting

Local validation asks whether a technology fits the population, infrastructure and workflow in which it will be used. Supplier results are an input to that assessment.

MHRA / NHS guidance
02 / Accountability

People who can act

Governance needs named responsibilities, risk review, staff education and a way to bring issues to the right decision-makers. Joint Commission/CHAI guidance sets out these connected practices.

Joint Commission / CHAI guidance
03 / Continuity

Review beyond go-live

Changes in data, local conditions and the technology itself can affect performance. Monitoring and supplier updates need a route back into review and action.

MHRA / NHS monitoring guidance
Different uses. Different review questions.

Start with the work AI is doing.

Explore practical review questions for five healthcare settings. These are suggested governance approaches; the required controls depend on the function, jurisdiction and your organization’s role.

01Ambient scribing & clinical documentationFrom a consultation to a draft note and clinician-reviewed record.
Questions for the team
Who checks omissions and errors? How are patients informed? What happens to recordings, transcripts and supplier logs?
Build the record in Liquid Learn
Capture the approved scope, data path, human review point and references to privacy, supplier and local evaluation evidence.
Revisit when
A new language, specialty, template, supplier model or recording-retention arrangement.
NHS England · Using ambient scribes
02Clinical decision support & diagnostic AITools that inform a clinical recommendation, prioritization or interpretation.
Questions for the team
What is the precise intended use and device status? Does the evidence cover local patients and relevant subgroups? What can a clinician independently review?
Build the record in Liquid Learn
Connect the service owner, validated scope, known limitations, human decisions and references to evaluation and regulatory documentation.
Revisit when
A changed threshold, model version, patient population or intended clinical use.
FDA · Clinical decision support guidance
03Patient communications & navigationDrafted messages, appointment guidance and patient-facing conversational tools.
Questions for the team
Where does administration become clinical advice? How are urgent concerns escalated, AI use explained and unsuitable outputs handled?
Build the record in Liquid Learn
Map approved content, data access, accountable reviewers and handoffs to qualified staff; reference the relevant transparency and safety review.
Revisit when
New advice categories, broader record access or a change in the human handoff.
Joint Commission / CHAI · Responsible use guidance
04Operational agents & administrative automationReferral routing, scheduling, coding support and other AI-assisted operations.
Questions for the team
Which actions can the agent take? Could an error affect access to care, reimbursement or a patient record? Who handles exceptions and recovery?
Build the record in Liquid Learn
Show tool and system boundaries, permitted actions, human approval points and references to testing and exception-handling procedures.
Revisit when
Expanded permissions, a new downstream system or a change from drafting to acting.
Joint Commission / CHAI · Responsible use guidance
05AI embedded in purchased softwareNew AI features within an EHR, imaging product or other supplier platform.
Questions for the team
Which function and version are being introduced? What evidence and change notices will the supplier provide? Who decides whether local review is needed?
Build the record in Liquid Learn
Connect supplier dependencies, intended use, local owners and change evidence to the service that relies on the feature.
Revisit when
A supplier release, altered model or revised terms for secondary data use.
MHRA / NHS · Monitoring after deployment
Pharmaceuticals & biotechnology

Bring governance to AI across the medicines lifecycle.

For sponsors, pharmaceutical and biotech teams, contract research organizations and manufacturing partners. Connect the AI workflow to its scientific purpose, accountable people and supporting evidence, from discovery through ongoing safety and quality work.

FDA/EMA’s good AI practice principles emphasize a defined context of use, data documentation, proportionate assessment and lifecycle management. Liquid Learn can organize the governance record around that work; scientific and regulated validation remain specialist activities. Read the joint principles.

01Drug discovery & clinical developmentAI used to prioritize research or generate and analyze evidence for development decisions.
Questions for the team
Is the output exploratory or intended to support a regulatory decision? What is the context of use, and what evidence supports the model’s suitability?
Build the record in Liquid Learn
Map the research workflow, data and supplier boundaries. Reference the evaluation plan, data provenance and scientific review alongside accountable owners.
Revisit when
A new dataset, study population, model version or move from research exploration to regulatory use.
FDA / EMA · Good AI practice in drug development
02Regulatory writing & medical informationAI-assisted literature synthesis, document drafting and responses prepared for expert review.
Questions for the team
Can reviewers trace statements to approved sources? Who checks accuracy, confidential information and the intended audience before release?
Build the record in Liquid Learn
Connect the drafting service to its source boundaries, human approval points and references to controlled documents and review evidence.
Revisit when
Updated source material, a changed drafting model or expansion into a new document or response type.
EMA · AI in the medicinal product lifecycle
03Pharmacovigilance & safety operationsAI-assisted literature screening, safety information extraction and case-processing support.
Questions for the team
How are missed or incorrect outputs assessed? Who reviews exceptions and owns any required safety reporting? How are sensitive case details protected?
Build the record in Liquid Learn
Describe AI and human handoffs, safety-team responsibilities and escalation controls. Reference evaluation and procedure evidence held in approved systems.
Revisit when
A new product, language, information source or change in the model’s role in safety review.
FDA / EMA · Good AI practice in drug development
04Manufacturing & quality operationsAI-assisted process analysis, deviation investigation and quality-document preparation.
Questions for the team
Could the output affect product quality or a release decision? Who determines GxP scope, validation needs and change approval?
Build the record in Liquid Learn
Connect the process, model dependencies, quality owners and control points. Reference validation, change-control and training evidence without replacing the quality system.
Revisit when
A changed process, site, input source, model or permitted action.
EMA · AI in the medicinal product lifecycle

Keep trial, safety and quality source records in approved systems. Scope any GxP (Good Practice) use with your quality team, including validation, data integrity, retention and electronic-record requirements. Review the product’s role and limits.

Healthcare & pharma need → Liquid Learn capability

Connect the review to the people, controls and evidence.

Use the platform to organize the governance work around each service. Your clinical, scientific, quality, privacy and regulatory specialists determine what is appropriate and carry out the underlying assurance.

01 / Service maps & boundaries

Know where AI enters the service

An inventory name alone does not explain who uses an output or where patient, participant or research information goes.

Map people, applications, AI steps, data stores and external providers. Describe intended use and the handoffs that need review.

The record you buildA service map with scope, data classifications and accountable owners.

Your team’s part: Your team identifies and maintains the inventory; this is not automatic discovery of every AI tool.

02 / Ownership & human oversight

Make clinical and quality accountability explicit

Clinical, scientific, quality and supplier teams may each own a different part of the same workflow.

Locate human review, approval and escalation points alongside AI activity. Record the roles responsible for decisions and exceptions.

The record you buildAn oversight model showing who reviews, who acts and where the fallback belongs.

Your team’s part: Clinical and quality authority, staffing and actual stop or override controls remain with your organization.

03 / Controls & evidence references

Review data use across suppliers

Prompts, transcripts, outputs, logs and support access can cross different contractual and technical boundaries.

Associate data classifications and control notes with service steps and connections. Reference privacy assessments, supplier terms and security reviews.

The record you buildA reviewable account of data movement, safeguards and the documents supporting them.

Your team’s part: Contracts, access controls and retention rules must be agreed and implemented in the relevant systems.

04 / Review packets & service snapshots

Connect local validation to approval

Performance in a supplier study may not establish suitability for your patients, study data, staff or regulated process.

Bring references to local evaluations, subgroup analyses and workflow tests into the review. Retain the service version, reviewer details and comments.

The record you buildA decision record with the evidence considered, its limitations and unresolved questions.

Your team’s part: Clinical or GxP validation, bias testing and performance measurement are performed separately.

05 / Regulatory ingestion & obligation tracking

Keep obligations tied to the use case

A device function, a drug-development model and an administrative agent can have different requirements.

Use configured sources, extracted obligations and profile-based matching to organize requirements with their document and version context.

The record you buildRequirements linked to source context, owners and applicability review.

Your team’s part: Specialists confirm classification and applicability; source coverage must be configured and checked.

06 / Training & certification tracking

Prepare the people doing the work

Staff need to understand approved uses, output limitations, relevant procedures and escalation.

Target training requirements to roles or teams, set due dates and review completion, outstanding assignments and available certificates.

The record you buildLearning records that can support the service’s oversight and readiness review.

Your team’s part: Your team chooses appropriate learning and assesses competence; completion is not clinical credentialing.

07 / Version context & ongoing review

Revisit the decision when things change

A model update, new population or changed workflow can undermine the assumptions behind approval.

Keep reviewed service snapshots and evidence references available for the next assessment. Record review comments against the service being considered.

The record you buildA history that helps reviewers compare scope, supporting evidence and decisions.

Your team’s part: Teams and suppliers operate monitoring, incident response and any required regulatory reporting.

08 / Metering & cost allocation

Bring operational use into the discussion

Governance owners also need to understand where activity and cost are accumulating.

Relate available metered usage and costs to responsible teams, services or business units alongside the governance record.

The record you buildOperational context to help question whether recorded use matches the agreed service scope.

Your team’s part: Usage metering does not measure clinical outcomes, detect model drift or establish patient benefit.

Liquid Learn’s service map interface showing systems, AI activity, data stores and boundaries.
Actual Liquid Learn interface · Illustrative service data.
Inside the platform

See the dependencies behind the decision.

A shared service map gives reviewers context for controls, ownership and evidence. Model the healthcare workflow you need to govern, then connect its review work.

Explore the product workspace See training rollout and tracking
Worked example · Ambient documentation

From a draft note to a reviewable service.

Model the path from a consultation to a reviewed record, including the supplier boundary and the clinician’s decision. This is an illustrative governance model, not a clinical-system integration or a patient record.

  1. 01

    Consultation

    Patient information & agreed use

    Reference the communication procedure and approved recording scope.

  2. 02

    AI draft

    Supplier & data boundaries

    Identify the provider, model context and retention arrangements.

  3. 03

    Clinical review

    Human responsibility

    Record who checks the draft and the fallback for unsuitable output.

  4. 04

    Record handoff

    Approved destination

    Document the control before reviewed content enters the clinical record.

  5. 05

    Ongoing review

    Evidence & change

    Bring evaluation references and supplier changes back to the service owner.

Bring the supporting evidence to review

Reference the approved-use policy, supplier due diligence, privacy assessment, local evaluation, training records and monitoring plan. Keep source evidence in its approved system and use references that do not expose patient information.

A supplier changes the model. What next?

Revisit the mapped scope and prior review with the clinical owner, digital team and relevant specialists. Record the evidence considered, remaining questions and decision against the service version.

For use in England, NHS guidance emphasizes approved tools, patient transparency and checking generated notes before they enter the record. Read the ambient scribe guidance

Regulatory context

Keep the function, the role and the jurisdiction in view.

Care delivery and medicines development have distinct regulatory contexts. A healthcare setting does not make every AI use a medical device. Use the starting points below for clinical services and the pharma-specific references for drug and biologic work.

United States

Device scope, health data & health IT

FDA’s January 2026 final CDS guidance addresses function-specific device exclusions. HIPAA cloud arrangements require attention to business-associate status, agreements and risk analysis where applicable.

The HTI-5 final rule changes relevant DSI certification requirements on December 28, 2026. These certification rules do not cover every hospital AI tool; retain appropriate supplier evidence commitments through the transition.

Read the medical AI guide
England

Clinical safety in deployment

NHS adopter guidance distinguishes DCB0129 for developers and DCB0160 for deploying organizations. Clinical risk management needs competent people, evidence and attention through the lifecycle.

Bring references to clinical safety and data protection work into your service review. Required safety documentation, assessments and sign-off remain specialist responsibilities.

Explore the UK context
European Union

AI Act & medical-device overlap

Assess provider and deployer roles, intended use and any medical-device overlap. Keep data protection and existing device duties in scope alongside the AI Act.

The July 2026 amendment moves Annex III high-risk rules to December 2, 2027 and the Annex I route to August 2, 2028. A later deadline for one provision does not postpone every obligation.

Explore the EU AI Act guide

Sources reviewed . Educational context, not legal advice. The mappings on this page are suggested operating practices; using Liquid Learn does not certify compliance. How we review sources.

Healthcare & pharma reading room

Bring the right context to your next review.

Our guides bring together official sources, scope questions and practical governance records. Explore medical AI for care delivery and the FDA/EMA references below for pharmaceutical work.

Establish a starting point with your team.

The 24-question AI Governance Health Check offers an immediate result and downloadable PDF roadmap. Use it to start a discussion; it is a general maturity assessment, not a clinical safety assessment.

Take the governance health check
Planning your evaluation

Agree the scope before you connect the data.

Can we use patient information in Liquid Learn?

Start with synthetic examples and evidence references that do not expose patient information. PHI handling, contractual terms including any BAA, deployment security and suitability must be confirmed separately before considering patient-data use. This page does not establish HIPAA suitability or authorization to store PHI.

Does this replace clinical validation or our quality system?

Liquid Learn organizes service governance, controls and review evidence. Your specialists perform clinical validation, determine device status and maintain required clinical safety and quality-system processes. The platform does not provide medical-device authorization, clinical decision-making or automatic compliance certification.

Can Liquid Learn replace a validated pharma system?

Liquid Learn supports governance around AI workflows. It is not presented here as a validated GxP system, electronic trial master file, pharmacovigilance database or batch-release system. Any regulated use needs a separate suitability and validation assessment by your quality team. This page does not establish compliance with 21 CFR Part 11 or EU GMP Annex 11. Required audit trails, electronic signatures, record retention and source-system controls must be evaluated separately.

Does Liquid Learn connect directly to our EHR or monitor model safety?

Service mapping describes systems and their boundaries; it does not imply a live EHR, FHIR or medical-device integration. Any integration must be scoped and confirmed. Clinical outcome measurement, drift detection and safety monitoring operate in the appropriate clinical and technical systems; their evidence can inform governance reviews.

Can our implementation or governance partner join the work?

Explore a delivery approach with your governance advisers or system integrator. Agree the scope, responsibilities, access and commercial arrangements for your organization. Learn about Liquid Learn partnerships.

A demo around your service

Bring one healthcare or pharma use case. Explore the governance around it.

Tell us what AI is doing, which team owns it and what your next review needs to establish. We’ll explore how service mapping, controls, evidence and training tracking could fit your workflow.

Useful people to include

A clinical, scientific or process owner, a digital lead and a colleague from quality, privacy or governance.

Useful context to bring

The intended use, supplier dependencies and current review process. Please use a description without patient or trial-participant details, confidential research or other sensitive information.

Review health-data considerations

Loading demo options…

Your enquiry details

We use your details to respond to this enquiry. Minimal advertising conversion reporting is optional and separate. How we handle submitted information is explained in our privacy notice.

Email directly